Umbellatine
Inherited Lipid Metabolism Disorder
China National Center for Cardiovascular DiseasesSmall moleculePhase 4 / ApprovedActive
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
17 Active assets in the Inherited Lipid Metabolism Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atorvastatin Johns Hopkins University | Phase 4 | A |
Rosuvastatin Korea University Anam Hospital | Phase 4 | A |
Metformin RenJi Hospital | Phase 4 | BBB |
Ezetimibe Samsung Medical Center | Phase 4 | BBB |
Simvastatin Eli Lilly and Company | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Umbellatine is also rated in:
metabolic dysfunction-associated steatotic liver diseaseActive
BB
Indicative · Phase 4
69 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →